Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Immune Checkpoint Inhibitors with or without Propranolol Hydrochloride for the Treatment of Urothelial Cancer

Trial Status: active

This clinical trial studies the effect of propranolol hydrochloride with or without immune checkpoint inhibitors (pembrolizumab, nivolumab, or avelumab) in treating patients with urothelial cancer. Propranolol hydrochloride is used for the treatment of chronic angina, cardiac arrhythmias, essential tremor, and hypertension, and as prophylaxis for migraine headaches, and may have anticancer properties. Immunotherapy with monoclonal antibodies, such as pembrolizumab, nivolumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.